Perspectives on targeted nano-drug carriers for tumor treatment

XU Yuhong; CAO Jing

doi:10.11665/j.issn.1000-5048.20130602

Journal of China Pharmaceutical University > 2013 > 44(6): 494-503. > DOI: 10.11665/j.issn.1000-5048.20130602

XU Yuhong, CAO Jing. Perspectives on targeted nano-drug carriers for tumor treatment[J]. Journal of China Pharmaceutical University, 2013, 44(6): 494-503. DOI: 10.11665/j.issn.1000-5048.20130602

Citation:

XU Yuhong, CAO Jing. Perspectives on targeted nano-drug carriers for tumor treatment[J]. Journal of China Pharmaceutical University, 2013, 44(6): 494-503. DOI: 10.11665/j.issn.1000-5048.20130602

Citation:

XU Yuhong, CAO Jing. Perspectives on targeted nano-drug carriers for tumor treatment[J]. Journal of China Pharmaceutical University, 2013, 44(6): 494-503. DOI: 10.11665/j.issn.1000-5048.20130602

PDF (1150 KB)

Perspectives on targeted nano-drug carriers for tumor treatment

XU Yuhong,
CAO Jing

More Information

Graphical Abstract

Abstract

Abstract

Recent advances in nanotechnology raises exciting opportunities for generating new cancer therapies that might allow more efficient targeted delivery of anticancer agents to kill tumors and imaging agents for diagnosis of various cancers. In this article, some new perspectives were provided on the development of targeted nano-drug carriers for cancer treatment. The focus was not to review research articles published on the subject, but to discuss issues we considered critical concerning target selection, targeting mechanism, and carrier structure design. We hope such discussions would encourage more detailed and careful studies to support product development of targeted drug carriers for cancer treatment.
- tumor targeting,
- nano-drug carriers,
- target selection,
- targeting mechanism

FullText(HTML)

References (76)

References

[1]	Ruoslahti E,Bhatia SN,Sailor MJ.Targeting of drugs and nanoparticles to tumors[J].J Cell Biol,2010,188(6):759-768.
[2]	Sumer B,Gao J.Theranostic nanomedicine for cancer[J].Nanomedicine,2008,3(2):137-140.
[3]	Cheng ZL, Al Zaki A, Hui JZ, et al. Multifunctional nanoparticles:cost versus benefit of adding targeting and imaging capabilities[J].Science,2012,338(6 109):903-910.
[4]	Uskokovic V.Entering the era of nanoscience:time to be small[J].J Biomed Nanotechnol,2013,9(9):1 441-1 470.
[5]	Fassas A,Anagnostopoulos A.The use of liposomal daunorubicin(DaunoXome)in acute myeloid leukemia[J].Leuk Lymphoma,2005,46(6):795-802.
[6]	Allen TM,Cullis PR.Drug delivery systems:entering the mainstream[J].Science,2004,303(5 665):1 818-1 822.
[7]	Allison SD.Liposomal drug delivery[J].J Infus Nurs,2007,30(2):89-95.
[8]	White SC,Lorigan P,Margison GP,et al.Phase II study of SPI-77(sterically stabilized liposomal cisplatin)in advanced non-small-cell lung cancer[J].Br J Cancer,2006,95(7):822-828.
[9]	Stathopoulos GP,Boulikas T.Lipoplatin formulateon review article[J].J Drug Deliv,2012:581363.doi: 10.1155/2012/581363.
[10]	Jeffrey AS,Steven RD.Marqibo^®(vincristine sulfate lposome injection)improves the pharmacyetics and pharmacys of vincristine[J].Cancer Chemo Pharmacol,2013,71(3):555-564.
[11]	Jaeckle KA,Batchelor T,O′Day SJ,et al.An open label trial of sustained-release cytarabine(DepoCyt)for the intrathecal treatment of solid tumor[J].J Neurooncol,2002,57(3):231-239.
[12]	Neville ME,Boni LT,Pflug LE,et al.Biopharmaceutics of liposomal interleukin 2,oncolipin[J].Cytokine,2000,12(11):691-701.
[13]	Clamp AR,Schoffski P,Valle JW,et al.A phase I and pharmacokinetic study of OSI-7904L,a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer[J].Cancer Chemother Pharmacol,2008,61(4):579-585.
[14]	Guo W,Johnson JL,Khan S,et al.Paclitaxel quantification in mouse plasma and tissue containing liposome-entrapped paclitaxel by liquid chromate-tandem mass spectrometry:application to a pharmacokinetics study[J].Anal Biochem,2005,336(2):213-220.
[15]	Balogh L,Bielinska A,Eichman JD,et al.Dendrimer nanocomposites in medicine[J].Chim Oggi,2002,20:35-40.
[16]	Seiden MV,Muggia F,Astrow A,et al.A phase II study of liposomal lurtotecan(OSI-211)in patients with topotecan resistant ovarian cancer[J].Gynecol Oncol,2004,93(1):229-232.
[17]	Dragovich T,Mendelson D,Kurtin S,et al.A phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer[J].Cancer Chemother Pharmacol,2006,58(6):759-764.
[18]	Lee KS,Chung HC,Im SA,et al.Multicenter phase II trial of Genexol-PM,a Cremophor-free,polymeric micelle formulateon of paclitaxel,in patients with metastatic breast cancer[J].Breast Cancer Res Treat,2008,108(2):241-250.
[19]	Matsumura Y,Hamaguchi T,Ura T,et al.Phase I clinical trial and pharmacokinetic evaluation of NK911,a micelle-encapsulated doxorubicin[J].Br J Cancer,2004,91(10):1 775-1 781.
[20]	Danson S,Ferry D,Alakhov V,et al.Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin(SP1049C)in patients with advanced cancer[J].Br J Cancer,2004,90(11):2 085-2 091.
[21]	Uchino H,Matsumura Y,Negishi T,et al.Cisplatin-incorporating polymeric micelles(NC-6004)can reduce nephrotoxicity and neurotoxicity of cisplatin in rats[J].Br J Cancer,2005,93(6):678-687.
[22]	Koizumi F,Kitagawa M,Negishi T,et al.Novel SN-38-incorporating polymeric micelles,NK012,eradicate vascular endothelial growth factor-secreting bulky tumors[J].Cancer Res,2006,66(20):10 048-10 056.
[23]	Hamaguchi T,Kato K,Yasui H,et al.A phase I and pharmacokinetic study of NK105,a paclitaxel-incorporating micellar nanoparticle formulation[J].Br J Cancer,2007,97(12):170-176.
[24]	Boddy AV,Plummer ER,Todd R,et al.A phase I and pharmacokinetic study of paclitaxel poliglumex(XYOTAX),investigating both 3-weekly and 2-weekly schedules[J].Clin Cancer Res,2005,11(21):7 834-7 840.
[25]	Bilim V.Technology evaluation:PK1,Pfizer/Cancer Research UK[J].Curr Opin Mol Ther,2003,5(3):326-330.
[26]	Meerum Terwogt JM,ten Bokkel Huinink WW,Schellens JH,et al.Phase I clinical and pharmacokinetic study of PNU166945,a novel water-soluble polymer-conjugated prodrug of paclitaxel[J].Anticancer Drugs,2001,12(4):315-323.
[27]	Bissett D,Cassidy J,de Bono JS,et al.Phase I and pharmacokinetic(PK)study of MAG-CPT(PNU 166148):a polymeric derivative of camptothecin(CPT)[J].Br J Cancer,2004,91(1):50-55.
[28]	Rademaker-Lakhai JM,Terret C,Howell SB,et al.A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors[J].Clin Cancer Res,2004,10(10):3 386-3 395.
[29]	Campone M,Rademaker-Lakhai JM,Bennouna J,et al.Phase I and pharmacokinetic trial of AP5346,a DACH-platinum-polymer conjugate,administered weekly for three out of every 4 weeks to advanced solid tumor patients[J].Cancer Chemother Pharmacol,2007,60(4):523-533.
[30]	Danhauser-Riedl S,Hausmann E,Schick HD,et al.Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin(AD-70,DOX-OXD)[J].Invest New Drugs,1993,11(2/3):187-195.
[31]	Shiose Y,Kuga H,Yamashita F,et al.Quantitative acid hydrolysis of DE-310,a macromolecular carrier system for the camptothecin analog DX-8951f[J].J Pharm Biomed Anal,2007,43(4):1 290-1 296.
[32]	Rowinsky EK,Rizzo J,Ochoa L,et al.A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies[J].J Clin Oncol,2003,21(1):148-157.
[33]	Sapra P,Zhao H,Mehlig M,et al.Novel delivery of SN38 markedly inhibits tumor growth in xenografts,including a camptothecin-11-refractory model[J].Clin Cancer Res,2008,14(6):1 888-1 896.
[34]	Schluep T,Hwang J,Cheng J,et al.Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models[J].Clin Cancer Res,2006,12(5):1 606-1 614.
[35]	NektarTherapeutics.Study to Evaluate the Safety and Efficacy of NKTR-102(PEG-Irinotecan)in Patients With Metastatic or Locally Advanced Breast Cancer[EB/OL].Clinical Trials,2008,[online],http://clinicaltrials.gov/ct2/show/NCT00802945.
[36]	Gradishar WJ,Tjulandin S,Davidson N,et al.Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer[J].J Clin Oncol,2005,23(31):7 794-7 803.
[37]	Cho K,Wang X,Nie S,et al.Therapeutic nanoparticles for drug delivery in cancer[J].Clin Cancer Res,2008,14:1 310-1 316.
[38]	Koumoutsakos P,Pivkin I,Milde F.The fluid mechanics of cancer and its therapy[J].Annual Review Fluid Mechanics,2013,45:325.
[39]	Carmeliet P,Jain RK.Angiogenesis in cancer and other diseases[J].Nature,2000,407:249-257.doi: 10.1038/35025220.
[40]	Kirpotin DB,Drummond DC,Shao Y,et al.Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models[J].Cancer Res,2006,66(13):6 732-6 740.
[41]	Mamot C,Drummond DC,Hong K,et al.Liposome-based approaches to overcome anticancer drug resistance[J].Drug Resist Updat,2003,6(5):271-279.
[42]	Matsumura Y,Gotoh M,Muro K,et al.Phase I and pharmacokinetic study of MCC-465,a doxorubicin(DXR)encapsulated in PEG immunoliposome,in patients with metastatic stomach cancer[J].Ann Oncol,2004,15(3):517-525.
[43]	MedBiopharm Co.L.Safety study of MBP-426(liposomal oxaliplatin suspension for injection)to treat advanced or metastatic solid tumors[EB/OL].ClinivalTrials.gov web site 2008,[online],http;//www.clinicaltrials.gove/ct/show/NCT00355888/
[44]	SynerGene Therapeutics I.safety study of infusion of SGT-53 tp treat solid tumors[EB/OL].ClinicalTrials,2008,[online].http://www.clincaltrials.gov/ct2/show/NCT004706 13/.
[45]	Calando-Pharmaceuticals.Safety study of CALAA-01 to treat solid tumor cancers[EB/OL].ClinicalTrials,2008,[online].http://www.clincaltrials.gov/ct/show/NCT0068 9065.
[46]	Daniels TR, Bernabeu E, Rodríguez JA, et al. The transferrin receptor and the targeted d?????ひ???扦爠??孥??嵰?卵慴摩汣漠湡潧癥慮????潧睡敩????乣潡癮慣步?婛??椮?敩琾?慩汯???業??摩敯湰瑨楹晳椠捁慣瑴楡漼港?漾昬′洰漱氲攬挼畢氾愱爠?搲椰猼琯楢渾挨琳椩漺渲猹?戭攳琱眷攮攼湢?港漾牛洴愷汝?打牯敮慧猠瑓?愬獌獩潵挠楄愬瑐敥摮?映楊扌爬漼扩氾慥獴琠獡?愮渼搯?戾牎敯慶獥瑬?捰慥湰捴敩牤?愠獬獩潧捡楮慤琠敤摩?晥楣扴牳漠扬汩慰獯瑳獯孭?嵳??楯??慲湤挠故片??楒挠牨潩敧湨瘭楥牸潰湲??楳????っ???扥?㈠??扬????????ㄠ??扴牲??嬯??崠?偮牤愼歩愾猠桩???摩敶??漯湩朾???倮漼獩琾????楂?敊琬?愯汩???椰???湢漾瘲攳氼?慢瀾瀨爵漩愺挱栠″琹漶?搱攠水椰瘴攮爼?慲港琾楛挴愸湝挠敄牡?摨物略杲猠?琬漠?歲敯祭?据攠求氬?瑌祥灣敯獵?極湲?瑥畲洠潎爼獩￣甬猠楥湴朠?慬?值????牔敡捲敧灥瑴潩牮?戠楯湦搠楴湵杭?捲礠捥汮楤捯?灨敥灬瑩極摭攠?捹漠湒瑇慄椭湧楲湡杦?捥慤爠牐楌敇牁嬭?嵡??楰????潣湬瑥牳漠汬?剡敤汥敤愠獷敩??椠???ぬ?ぴ??扥??????扩??㈠??????ぬㄠ?elease,2009,140(2):166-173.
[47]	Liu XQ,Song WJ,Sun TM,et al.Targeted delivery of antisense inhibitor of miRNA for antiangiogenesis therapy using cRGD-functionalized nanoparticles[J].Mol Pharm,2011,8(1):250-259.
[48]	Mai JH, Song SX, Rui MJ, et al. A synthetic peptide mediated active targeting of cisplatin liposomes to Tie2 expressing cells[J].J Control Release,2009,139(3):174-181.
[49]	Winer I,Wang S,Lee YE,et al.F3-targeted cisplatin-hydrogel nanoparticles as an effective therapeutic that targets both murine and human ovarian tumor endothelial cells in vivo[J].Cancer Res,2010,70(21):8 674-8 683.
[50]	Guo J,Gao X,Su L,et al.Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery[J].Biomaterials,2011,32(31):8 010-8 020.
[51]	Yu DH, Lu Q, Xie J, et al. Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature[J].Biomaterials,2010,31(8):2 278-2 292.
[52]	Deshayes S,Maurizot V,Clochard MC,et al.“Click” conjugation of peptide on the surface of polymeric nanoparticles for targeting tumor angiogenesis[J].Pharm Res,2011,28(7):1 631-1 642.
[53]	Hong H,Yang K,Zhang Y,et al.In vivo targeting and imaging of tumor vasculature with radiolabeled,antibody-conjugated nanographene[J].ACS Nano,2012,6(3):2 361-2 370.
[54]	Ruggiero A,Villa CH,Holland JP,et al.Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes[J].Int J Nanomedicine,2010,5:783-802.doi.10.2147/IJN.S13300.
[55]	Jubeli E,Moine L,Nicolas V,et al.Preparation of E-selectin-targeting nanoparticles and preliminary in vitro evaluation[J].Int J Pharm,2012,426(1/2):291-301.
[56]	Mann AP,Bhavane RC,Somasunderam A,et al.Thioaptamer conjugated liposomes for tumor vasculature targeting[J].Oncotarget,2011,2(4):298-304.
[57]	Mosser DM,Edwards JP.Exploring the full spectrum of macrophage activation[J].Nat Rev Immunol,2008,8(12):958-969.
[58]	Mantovani A,Sica A.Macrophages,innate immunity and cancer:balance,tolerance,and diversity[J].Curr Opin Immunol,2010,22(2):231-237.
[59]	Steidl C,Lee T,Shah SP,et al.Tumor-associated macrophages and survival in classic Hodgkin′s lymphoma[J].N Engl J Med,2010,362(10):875-885.
[60]	Low PS,Henne WA,Doorneweerd DD.Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases[J].Acc Chem Res,2008,41(1):120-129.
[61]	Segers FME,Yu H,Molenaar TJ,et al.Design and validation of a specific scavenger receptor class AI binding peptide for targeting the inflammatory atherosclerotic plaque[J].Arterioscler Thromb Vasc Biol,2012,32(4):971-978.
[62]	Cieslewicz M,Tang JJ,Yu JL,et al.Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival[J].PNAS,2013,110(40):15 919-15 924.
[63]	Adams JM,Strasser A.Is tumor growth sustained by rare cancer stem cells or dominant clones[J]? Cancer Res,2008,68(11):4 018-4 021.
[64]	Nakai E,Park K,Yawata T,et al.Enhanced MDR1 expression and chemoresistance of cancer stem cells derived from glioblastoma[J].Cancer Invest,2009,27(9):901-908.
[65]	Eramo A,Lotti F,Sette G,et al.Identification and expansion of the tumorigenic lung cancer stem cell population[J].Cell Death Differ,2008,15(3):504-514.
[66]	Li C,Heidt DG,Dalerba P,et al.Identification of pancreatic cancer stem cells[J].Cancer Res,2007,67:1 030-1 037.
[67]	Lee CJ,Dosch J,Simeone DM.Pancreatic cancer stem cells[J].J Clin Oncol,2008,26(17):2 806-2 812.
[68]	Boman BM,Huang E.Human colon cancer stem cells:a new paradigm in gastrointestinal oncology[J].J Clin Oncol,2008,26(17):2 828-2 838.
[69]	Cocciadiferro L,Miceli V,Kang KS,et al.Profiling cancer stem cells in androgen-responsive and refractory human prostate tumor cell lines[J].Ann NY Acad Sci,2009,1 155:257-262.
[70]	Schatton T,Murphy GF,Frank NY,et al.Identification of cells initiating human melanomas[J].Nature,2008,451(7 176):345-349.
[71]	Bussolati B,Bruno S,Grange C,et al.Identification of a tumor-initiating stem cell population in human renal carcinomas[J].FASEB J,2008,22(10):3 696-3 705.
[72]	Banzato A,Bobisse S,Rondina M,et al.Apaclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity[J].Clin Cancer Res,2008,14(11):3 598-3 606.
[73]	Upadhyay KK,Bhatt AN,Mishra AK,et al.The intracellular drug delivery and anti tumor activity of doxorubicin loaded poly(γ-benzyl L-glutamate)-b-hyaluronan polymersomes[J].Biomaterials,2010, 31(10):2 882-2 892.
[74]	Bourseau-Guilmain E,Bejaud J,Griveau A,et al.Development and characterization of immunonanocarriers targeting the cancer stem cell marker AC133[J].Int J Pharm,2011,423(1):93-101.
[75]	Yang ZF,Ho DW,Ng MN,et al.Significance of CD90+cancer stem cells in human liver cancer[J].Cancer Cell,2008,13(2):153-166.
[76]	Baum P,Müller D,Rüger R,et al.Single-chain Fv immunoliposomes for the targeting of fibroblast activation protein-expressing tumor stromal cells[J].J Drug Target,2007,15(6):

[1]	YANG Ruocong, DUAN Feipeng, CHAO Jiahong, TIAN Pengpeng, YAN Zhiyong, LI Shaojing. Advances of microRNA activity in innate immunity[J]. Journal of China Pharmaceutical University, 2017, 48(4): 396-406. DOI: 10.11665/j.issn.1000-5048.20170403
[2]	SI Lianghui, MA Hui, ZHOU Jinpei, ZHANG Huibin. Advances in antidiabetic small molecule ABHD6 inhibitors[J]. Journal of China Pharmaceutical University, 2017, 48(2): 125-134. DOI: 10.11665/j.issn.1000-5048.20170201
[3]	WU Shiwei, ZHANG Hui, LI Qianbin, HU Gaoyun. Advances in thioredoxin reductase and its inhibitors[J]. Journal of China Pharmaceutical University, 2016, 47(5): 511-520. DOI: 10.11665/j.issn.1000-5048.20160502
[4]	XIN Minhang, ZHANG Sanqi. Advances in PI3Kδ selective inhibitors[J]. Journal of China Pharmaceutical University, 2016, 47(5): 503-510. DOI: 10.11665/j.issn.1000-5048.20160501
[5]	YAO Guilin, WANG Haiyong, LU Tao. Advances of the uricosuric drugs[J]. Journal of China Pharmaceutical University, 2016, 47(4): 491-496. DOI: 10.11665/j.issn.1000-5048.20160417
[6]	LIU Kejun, ZHANG Zhimin, RAN Ting, CHEN Hongli, LU Tao, CHEN Yadong. Advances in BET bromodomain protein inhibitors[J]. Journal of China Pharmaceutical University, 2015, 46(3): 264-271. DOI: 10.11665/j.issn.1000-5048.20150302
[7]	LI Tonghui, GUO Hao, LU Tao, WANG Yue, LU Shuai, TANG Weifang. Advances in the research of FLT3 inhibitors for acute myeloid leukemia[J]. Journal of China Pharmaceutical University, 2015, 46(2): 153-161. DOI: 10.11665/j.issn.1000-5048.20150203
[8]	LI Chunhong, DU Hongjin, WEN Xiao′an, SUN Hongbin. Advances in inhibitors of MDM2 and MDM4[J]. Journal of China Pharmaceutical University, 2015, 46(1): 1-15. DOI: 10.11665/j.issn.1000-5048.20150101
[9]	Advances in the research of factor Xa inhibitors[J]. Journal of China Pharmaceutical University, 2010, 41(2): 104-111.
[10]	Advances in Selective COX-2 Inhibitors[J]. Journal of China Pharmaceutical University, 2003, (3): 1-6.

Cited By

Get Citation

PDF

XML

Article views (2410) PDF downloads (4067)

Turn off MathJax

Article Contents

Abstract

References

Perspectives on targeted nano-drug carriers for tumor treatment

Abstract

References

Related Articles

Catalog

Perspectives on targeted nano-drug carriers for tumor treatment

Abstract

References

Related Articles

Catalog

Export File

Citation

Format

Content